<DOC>
	<DOCNO>NCT00924950</DOCNO>
	<brief_summary>The purpose study determine whether use Taclonex ointment hydrogel patch effective use ointment alone treat psoriasis . Taclonex ointment currently FDA approve use psoriasis . The hydrogel patch type adhesive pad contains medication . It currently FDA approve show safe virtually free side effect . The hypothesis psoriatic plaque treat Taclonex ointment hydrogel patch effectively treat compare psoriatic plaque treat Taclonex alone .</brief_summary>
	<brief_title>Taclonex Ointment With Hydrogel Patch Occlusion Treatment Psoriasis</brief_title>
	<detailed_description>This open label , bilaterally-controlled single center study . Thirty subject plaque type psoriasis enrol study . All subject receive treatment two target lesion similar erythema , scale induration , symmetric anatomic location . The severity target lesion assess use modify Psoriasis Area Severity Index ( PASI ) score system ( Appendix A ) . Symmetrical target lesion must rat PASI score equal great 7 within 1 PASI score . All subject apply Taclonex ointment target lesion daily 4 week . The occlusive dressing apply subject one two symmetrical target lesion daily 4 week . The occlusive dressing remove patient he/she experience warmth , irritation , increase erythema , and/or itching . If patch remove due symptom sign , subject leave lesion un-occluded 24 hour , time new occlusive dressing place . After initial 4 week treatment , follow period 6 week treatment use . Subjects restrict use systemic therapy psoriasis study , include Psoralen Ultraviolet A ( PUVA ) photochemotherapy herbal therapy . All topical medication , except study medication , UVB phototherapy prohibit target lesion . All psoriasis lesion body treat usual topical medication Ultraviolet B ( UVB ) phototherapy long impact two target lesion .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>1 . Subject sign informed consent form Health Information Portability Accountability Act ( HIPAA ) authorization form ; 2 . Male female subject least 18 year age ; 3 . A diagnosis stable plaquetype psoriasis vulgaris least one pair symmetric lesion either trunk , arm , leg would serve target lesion . Paired target lesion must similar anatomic location ( e.g. , right leave elbows right left knee ) roughly equivalent ( one point difference ) modify Psoriasis Area Severity Index ( PASI ) score . Each pair target lesion must PASI score equal great 7 ; 4 . Any additional diagnosis must , investigator 's opinion , preclude subject safely participate study interfere evaluation subject 's psoriasis ; 5 . Psoriasis must clinically stable least 30 day enrollment ; 6 . Subject able discontinue use medication therapy relief psoriasis target area treat ; 7 . Subject able discontinue use systemic medication therapy ( e.g . oral injectable psoriasis medication , PUVA photochemotherapy , herbal remedy , etc . ) psoriasis ; 8 . Subject must reliable mentally competent complete study measurement ; 9 . Subject able understand agree comply study requirement , attend study visit , comply restriction study . 1 . Subject skin disorder psoriasis target area evaluate ; 2 . Known hypersensitivity component test medication ; 3 . Pigmentation , extensive scarring , pigment lesion affected area would interfere evaluation efficacy parameter ; 4 . Clinically infected psoriasis baseline ; 5 . Guttate , pustular , erythrodermic , nonplaque form psoriasis ; 6 . Spontaneously worsen improve psoriasis within 30 day enrollment ; 7 . Any evidence atrophy area select treatment topical corticosteroid ; 8 . Topical intralesional therapy ( emollient ) UVB phototherapy potential target lesion within two week start study treatment ; 9 . Systemic therapy , PUVA phototherapy , systemic investigational therapy psoriasis within 30 day prior study entry ; 10 . Treatment topical investigational therapy target lesion within 30 day prior study entry ; 11 . Subject consider unreliable medication compliance adherence schedule appointment determine investigator . 12 . Subject pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Plaque psoriasis , bilateral symmetrical lesion .</keyword>
	<keyword>A diagnosis stable plaque-type psoriasis vulgaris</keyword>
	<keyword>least one pair symmetric lesion either</keyword>
	<keyword>trunk , arm , leg would serve target lesion .</keyword>
</DOC>